	US 12,121,581 B2
	Method of photodynamic therapy
Georgios C. Vougioukalakis, Attica (GR); Georgios Rotas, Attica (GR); Theodossis A. Theodossiou, Oslo (NO); Kristian Berg, Heggedal (NO); and Ángel Miranda Alonso Miguel, Valencia (ES)
Assigned to OSLO UNIVERSITETSSYKEHUS HF, Oslo (NO); CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES); UNIVERSITAT POLITÉCNICA DE VALÊNCIA, Valencia (ES); and NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, Athens (GR)
Appl. No. 17/254,506
Filed by OSLO UNIVERSITETSSYKEHUS HF, Oslo (NO); CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, Madrid (ES); UNIVERSITAT POLITÉCNICA DE VALÈNCIA, Valencia (ES); and National and Kapodistrian University of Athens, Athens (GR)
PCT Filed Jun. 21, 2018, PCT No. PCT/GB2018/051744 § 371(c)(1), (2) Date Dec. 21, 2020, PCT Pub. No. WO2019/243757, PCT Pub. Date Dec. 26, 2019.
Prior Publication US 2021/0121570 A1, Apr. 29, 2021
Int. Cl. A61K 41/00 (2020.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61P 35/00 (2006.01)

CPC A61K 41/0057 (2013.01) [A61K 41/0061 (2013.01); A61K 47/545 (2017.08); A61K 47/55 (2017.08); A61P 35/00 (2018.01)]

9 Claims

1. A method of photodynamic therapy of cells or tissues of a patient, said method comprising administering to said cells or tissues an effective amount of a mitochondria-targeted chemiluminescent agent which is a conjugate comprising a chemiluminescent moiety attached to a mitotropic moiety and, simultaneously, separately, or sequentially thereto, an effective amount of a photosensitizer or a precursor thereof:

wherein said agent is a compound of formula (III), or a pharmaceutically acceptable salt thereof:

where L¹is a linker;

B¹is a mitotropic moiety which is the following group:

where R¹is phenyl, toluene, or cyclohexyl; and X is a monovalent anion;

R³is hydrogen, or an alkyl group;

each R⁴is independently selected from C_1-6alkyl, and —NR⁵R⁶;

R⁵and R⁶are independently selected from H and C_1-6alkyl; and

p is an integer from 0 to 3.